Michael Hollan

New York

Assistant Managing Editor at MJH Life Sciences

Assistant Managing Editor at Pharmaceutical Executive

Lifestyle writer for Fox News. Dog owner. I don't know what else to put here.

Featured in: Favicon

mjhlifesciences.com Favicon

foxnews.com Favicon

thesun.co.uk Favicon

yahoo.com (+2) Favicon

nypost.com Favicon

marketwatch.com Favicon

news.com.au Favicon

dailytelegraph.com.au Favicon

cbr.com

foxbusiness.com + 56 more

Articles

Strategizing for an Uncertain Trade War: Q&A with Anshul Mangal

1 month ago | pharmexec.com | Michael Hollan

The Project Farma president discusses various ways the tariffs could impact the industry and how businesses can prepare or react.
10 Tiny Ways To Be A Better Human — Today, Tomorrow And Always

Jul 2, 2024 | yourtango.com | Michael Hollan

We all want to be better people. It's a good thing, because it means most of us are trying to grow. That's the biggest part of being a good person: simply trying every once in a while. It all comes down to the little things. While it would be great if everyone could give up their worldly possessions and become community farmers and doctors, that's just not realistic. We all have lives to live and we can't just drop everything. But we can improve our day-to-day lives.
10 Movie Monsters That Could Defeat Godzilla (And 10 That Don’t Stand a Chance)

Apr 18, 2024 | cbr.com | Jordan Iacobucci |Michael Hollan |Anthony Jeanetta

By Jordan Iacobucci , Michael Hollan , and Anthony Jeanetta Updated 15 minutes ago He might be considered the king of the monsters, but there are plenty of other movie beasts that could dethrone Godzilla and steal the crown.
11 Painfully Honest Truths About Dating A Middle Child

Mar 23, 2024 | yourtango.com | Michael Hollan

I'm the middle child of three boys. All my life, I’ve heard people tell me, "I can tell that you're a middle child." It's the hardest position to grow up in, and you may develop middle-child syndrome. Oldest and youngest siblings have well-defined characteristics due to birth order, but the middle child is a real wild card. That said, if you’re dating a middle child, you might not know how to deal with them. But here are 11 things you'll always find to be true.
No, Polyamory Won't "Save" Your Marriage

Mar 17, 2024 | yourtango.com | Michael Hollan

Nothing, especially polyamory, is going to be able to fix your broken marriage. By Michael Hollan Last updated on Mar 17, 2024Photo: Robert Kneschke, rashadashurov, Jona_al | Canva Editor's Note: This is a part of YourTango's Opinion section where individual authors can provide varying perspectives for wide-ranging political, social, and personal commentary on issues. Would going to an intimate party with your spouse save your marriage? According to expert Louise Van der Velde, it definitely will.
Implications of Novo Nordisk Acquisition of Catalent Reverberate Through Industry

Feb 13, 2024 | pharmaceuticalcommerce.com | Michael Hollan

Novo Nordisk’s parent company recently announced that it has agreed to purchase Catalent. As part of the acquisition, Novo Nordisk will purchase three of Catalent’s manufacturing sites. This is part of a move by the company to increase its ability to meet the demand for Wegovy, a highly popular weight loss drug. Bruce Phelan, senior partner at Blue Fin, spoke with Pharmaceutical Executive about the larger impact that this purchase will have on the industry.
Survey: Pharma Execs Are Fully Embracing the Use of AI

Feb 13, 2024 | pharmaceuticalcommerce.com | Michael Hollan

Artificial intelligence (AI) is hitting pharma’s budgets, but not in the way you think. A new survey of pharma executives looked into the ways which pharma companies are incorporating AI into their business plans.1 According to the results, a significant number of pharma leaders are already so confident in the results that technology like generative AI can achieve that they’re adjusting their budgets.
Forecast Predicts Generic Drug Market Will Grow Upwards of $175B Over the Next Three Years

Feb 9, 2024 | pharmaceuticalcommerce.com | Michael Hollan

The generic drug market is expected to show significant growth in the coming years. At least, that’s according to a new study conducted by Technavio, a leading global technology research and advisory company.1 In a press release, the research company detailed the estimated growth, stating that it believes the market will grow by $176.25 billion by 2027. It also states that North America will contribute about 37% of this growth.
Evaluate Acquires J+D Forecasting

Jan 10, 2024 | pharmexec.com | Michael Hollan

Evaluate announced the acquisition of J+D Forecasting, a provider of forecasting solutions focused on the pharmaceutical and life sciences industry. The move will bring J+D under the Norstella umbrella, the parent company of Evaluate. The parent company also includes Citeline, MMIT, Panalgo, and The Dedham Group. Norstella works to bring therapies to patients and provide insights to pharmaceutical companies during the drug development life cycle.
HBA Announces 2024 Woman of the Year

Jan 9, 2024 | pharmexec.com | Michael Hollan

Dr. Yvonne Greenstreet is the 2024 Healthcare Businesswomen's Association (HBA) Woman of the Year. Greenstreet is the CEO of Alnylam, a pharmaceutical company focused on developing RNA interference therapeutics. The HBA also named Dr. Otis Johnson as its honorable mentor of the year, and awarded Dr. Katherine Schoenborn its annual STAR honor. The HBA will honor Greenstreet at its annual Woman of the Year event, which will take place on May 10 in New York City.